# US 2025/0375415 A1 · Enhancing autophagy or increasing longevity by administration of urolithins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375415 A1
- Document ID: US20250375415A1
- Status: Published application
- Kind: A1
- Application number: 19/311,619
- Filed: 2025-08-27
- Published: 2025-12-11
- Earliest claimed: 2012-06-27
- Assignees: Amazentis SA
- Applicants: Amazentis SA
- Inventors: Christopher L. Rinsch; William Blanco-Bose; Bernard Schneider; Laurent Mouchiroud; Dongryeol Ryu; Penelope Andreux; Johan Auwerx
- Web page: https://patentgrep.com/patent/US20250375415A1

## CPC

- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

## Claims

### Claim 1

A composition, comprising a urolithin or a pharmaceutically acceptable salt thereof; and creatine or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, urolithin C, urolithin D, and any combination thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the urolithin is urolithin A.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the urolithin is urolithin B.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the urolithin is urolithin C.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the urolithin is urolithin D.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising an acceptable carrier.

### Claim 8 (depends on 3)

The composition of claim 3, wherein the amount of urolithin A is about 250 mg.

### Claim 9 (depends on 3)

The composition of claim 3, wherein the amount of urolithin A is about 500 mg.

### Claim 10 (depends on 3)

The composition of claim 3, wherein the amount of urolithin A is about 1000 mg.

### Claim 11 (depends on 3)

The composition of claim 3, wherein the composition is an oral dosage form.

### Claim 12 (depends on 8)

The composition of claim 8, wherein the composition is an oral dosage form.

### Claim 13 (depends on 9)

The composition of claim 9, wherein the composition is an oral dosage form.

### Claim 14 (depends on 10)

The composition of claim 10, wherein the composition is an oral dosage form.
